abortion pill
FDA okays RU486 after years of controversy NEW YORK, Sep 28 (Reuters Health) - After 4 years of controversy and negotiation, the US Food and Drug Administration (FDA) on Thursday approved the abortion drug mifepristone, more commonly known as RU-486. The approval comes with some, but not all, of the prescribing restrictions originally discussed as conditions for getting the drug onto the market. Mifepristone, which will be sold under the trade name Mifeprex, will be available to doctors within about 4 weeks, according to Danco Laboratories, the New York City-based pharmaceutical company that will distribute and market the drug. The procedure for obtaining mifepristone is more burdensome than for other drugs, but the FDA's requirements surrounding the abortion drug are far less restrictive than they might have been. As recently as June, it appeared that prescribing of the drug might have been limited to doctors who were trained to perform surgical abortions, had facilities to monitor patients using ultrasound, and were located within an hour of emergency facilities. Dr. Carole Joffe, a professor at the University of California-Davis who studies abortion policy in the US, called the fact that the FDA will allow d
. . .
Some common words found in the essay are:
Family Foundation, University California-Davis, York City-based, Danco Bleeding, Heather O'Neil, Administration FDA, Life League, February Right-to-life, YORK Sep, , perform surgical, perform surgical abortions, told health, abortion drug, according danco, abortion services, access abortion, medical abortion, danco spokesperson, access abortion services, currently perform surgical, surgical abortions, takes tablets,
Approximate Word count = 801
Approximate Pages = 3 (250 words per page double spaced)
|
 |
